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The Cromer blood group system: a review
J.R. Storry, M.E. Reid, and M.H. Yazer
The antigens of the Cromer blood group 
system reside on decay-accelerating fac-
tor (DAF), a protein belonging to the 
regulators of complement activation 
family. The blood group system consists 
of 12 high-prevalence and three low-
prevalence antigens. The molecular ba-
sis for the antigens is known, and with 
the exception of IFC, each antigen is the 
product of a single nucleotide change in 
the DAF gene and has been localized to 
one of the four complement control pro-
tein (CCP) domains on the DAF protein. 
The RBCs of people with the Cromer 
null phenotype, Inab, lack DAF but do 
not appear to demonstrate increased 
susceptibility to hemolysis. Antibodies 
to Cromer antigens are rarely encoun-
tered, although there is evidence that 
the antibodies may cause accelerated 
destruction of transfused RBCs. There is 
no risk of HDN associated with Cromer 
system antibodies because the placenta 
is a rich source of fetally derived DAF, 
which is thought to adsorb the antibodies 
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The Cromer blood group antigens are carried on de-cay-accelerating factor (DAF, CD55), a member of a family of proteins known as the regulators of com-
plement activation. In 1965, an antibody in the serum of 
a Black prenatal patient, Mrs. Cromer, which reacted with 
all RBCs except her own and those of two siblings, was re-
ported.1 RBCs from Mrs. Cromer were Go(a+), and initially 
her antibody was named anti-Gob because it was thought 
to detect the high-prevalence antigen antithetical to Goa 
(Goa was only years later discovered to result from a par-
tial D rearrangement categorized as DIVa). In 1975, Stroup 
and McCreary2 reported four additional examples of the 
antibody and renamed it anti-Cra after the propositae. In 
1982, Daniels et al.3 described an antibody in the serum of 
a Japanese man (Inab) that was reactive with all RBCs, in-
cluding those of his mother, father, and brother. Inab RBCs 
were shown to be the null phenotype of the Cromer sys-
tem. Subsequently, other examples of antibodies to high- 
prevalence antigens were linked to Cromer by failure of 
the antibody to react with Inab RBCs, sensitivity of the an-
tigen to α-chymotrypsin treatment of RBCs, and specific 


















Cra CROM1 Ala227 Pro227






Dra CROM5 Ser199 Leu199
Esa CROM6 Ile80 Asn80
IFC CROM7
WESb CROM9 Leu82 WESa CROM8 Arg82
UMC CROM10 Thr250 Met250
GUTI CROM11 Arg240 His240
SERF CROM12 Pro216 Leu216
ZENA CROM13 His242 Gln242
CROV CROM14 Glu156 Lys156
CRAM CROM15 Gln247 Arg247
*Reprinted with permission from John Wiley and Sons.4
inhibition of the antibody by concentrated plasma or urine 
from an antigen-positive person. To date, 12 high-preva-
lence antigens and 3 low-prevalence antigens have been de-
scribed in the Cromer system (Table 1).4 Transfusion data 
regarding the clinical significance of antibodies to Cromer 
antigens are mixed; however, no cases of hemolytic disease 
of the fetus and newborn (HDFN) have been described. 
These clinical details are discussed later in more detail.
Cromer Blood Group Antigens Are Carried on DAF 
 In 1987, a human cell-surface glycoprotein with an 
approximate Mr of 70 kDa, found on RBCs, WBCs, and 
platelets, was characterized and shown to carry the Cromer 
antigens.5 Telen et al.6 and Parsons et al.7 showed inde-
pendently that this glycoprotein was DAF and that people 
with the Inab phenotype lacked DAF on their RBCs. DAF is 
linked to the cell membrane by a glycosylphosphatidylinosi-
tol (GPI) anchor and is expressed on all hematopoietic cells 
and on the vascular endothelium where it protects against 
complement-mediated attack.8 It is also widely expressed 
on epithelium in the gastrointestinal (GI), genitourinary, 
and central nervous systems. A soluble form is present in 
plasma and body fluids.9
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IMMUNOHEMATOLOGY, Volume 26, Number 3, 2010110
 The gene encoding DAF was mapped to chromosome 
1 in 1987.10 It was cloned and sequenced in the same year: 
DAF encodes a protein of 381 amino acids that includes 
a 34-residue signal peptide.11,12 The mature protein is ar-
ranged into four complement control protein (CCP) do-
mains, each of approximately 60 amino acids, followed by 
a 70-amino acid region that is rich in serine and threonine 
residues.8 In this review, for the numbering of nucleotides 
and amino acids in DAF, nucleotide A of the initiation 
methionine codon is designated as nucleotide 1 and the 
first amino acid (methionine) of the mature protein is des-
ignated as residue 1 (Fig. 1). These numbers may differ from 
those in the original reports.
 Before DAF was identified as the carrier protein for 
Cromer blood group antigens, traditional methods of es-
tablishing exclusion of new Cromer antigens from existing 
blood groups were used. These methods include compre-
hensive family studies and serologic characterization of the 
antibodies. Consanguinity has been shown in four families 
in which the propositus lacks a high-prevalence Cromer 
blood group antigen.14–17 DNA sequencing now provides a 
rapid method of identifying the genetic basis of the anti-
gens. Furthermore, two elegant sets of experiments, one 
using the monoclonal antibody immobilization of eryth-
rocytes assay (MAIEA)18 and the other using a series of 
DAF deletion mutant proteins expressed in Chinese ham-
ster ovary (CHO) cell lines, permitted epitope mapping of 
the antigens to one of the four CCPs on DAF (Fig. 2).20–22 
These experiments are important because although DNA 
sequencing can be used to identify a missense nucleotide 
change in DAF, proving that the change is responsible for 
the presence or absence of an antigen is difficult when there 
are only one or two examples of the phenotype to test. The 
MAIEA confirmed that Cromer antigens are on DAF, and 
the use of well-characterized monoclonal anti-DAF in com-
bination with human polyclonal antibodies to different 
Cromer antigens permitted spatial mapping. Western blot-
ting experiments using CHO cell lines that expressed all or 
part of the DAF protein were tested with specific antibod-
ies to Cromer antigens and the DAF protein. The results of 
these assays correlated with the DNA sequence predictions.
Characteristics of the Antigens and Antibodies
Cra
 The first example of anti-Cra was described in 1965 in 
the serum of a Black woman.1 The antibody reacted with 
the RBCs of all random donors and with those of more than 
4000 Black donors but not with the proposita’s own RBCs or 
those of two of her siblings. With the exception of one exam-
ple found in the serum of a Spanish American woman,23 all 
examples of anti-Cra have been found in Black individuals.24 
Although anti-Cra may be stimulated by pregnancy,25 there 
have been no cases of HDFN attributable to the antibody 
(see later discussion). The molecular basis of the Cr(a–) 
phenotype is a nucleotide change, 679G>C in exon 6, which 
is predicted to encode an amino acid substitution of Ala-
227Pro in the CCP4 of DAF.22 No low-prevalence antigen 
has been identified as being associated with this change.
Tca, Tcb, Tcc
 Tca, a high-prevalence antigen, was first reported in 
1980.26 The antibody was found in the serum of two Black 
women (GT and DLC), and the new antigen defined by the 
GT and DLC sera was named Tca after the two propositae. 




Figure 1.  The organization of the DAF gene.
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 ATG in exon 1 is the initiator codon, the A of which is nt-54.
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complement control protein (CCP) domains of the protein. The S/T region refers to the exons that encode a serine/threonine rich 








        Copyright 1990. The American Association of Immunologists, Inc.Fig. 1. The organization of the DAF gene. ATG in exon 1 is the initia-
tion codon, the A of which is nucleotide 1.8 Roman numerals indicate 
the region of the gene that encodes the complement control protein 
(CCP) domains of the protein. The S/T region refers to the exons 
that encode a serine/threonine-rich region. 3′ UTR is the 3′ untrans-
lated region. Reprinted with permission from the Journal of Immunol-
ogy.13 Copyright 1990. The American Association of Immunologists, 
Inc.
Fig. 2. Schematic diagram of the glycosylphosphatidylinositol-linked 
DAF protein demonstrating its four complement control protein 
(CCP) regions and the location of the Cromer antigens along with 
their amino acid mutations. Reprinted with permission from John 
Wiley and Sons.19
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Neither patient had been transfused. Presumably, their an-
tibodies had been stimulated by pregnancy, although there 
was no evidence of HDFN. The DLC antibody was distinct 
from all other antibodies to known high-prevalence anti-
gens. Tests with a panel of RBCs that lacked an unidentified 
high-prevalence antigen revealed compatibility with the 
RBCs from GT. Cross-testing confirmed that the antibodies 
were mutually compatible. Studies on 28 members of DLC’s 
family revealed two additional Tc(a–) people, neither of 
whom had produced anti-Tca.14 Previously, Stroup and Mc-
Creary2 had found that the RBCs from one of their Cr(a–) 
patients, AJ, reacted very weakly with the GT serum, and 
a possible relationship between the two antigens was pro-
posed. The RBCs of Inab were compatible with the “new” 
antibody; however, the Inab serum was reactive with RBCs 
from both AJ and DLC. The low-prevalence antigen Tcb 
was identified when the Tc(a–) RBCs of WM reacted with 
one of four sera containing anti-Goa.27 After adsorption of 
the anti-Goa, the serum reacted with 6 of 103 RBC samples 
from randomly selected Black individuals. Additionally, 
the RBCs of 11 Tc(a–) individuals were agglutinated by the 
absorbed serum. Thus, it was concluded that the new anti-
body detected an antigen, Tcb, which was antithetical to Tca. 
The occurence of Tcb in a random Black population was cal-
culated to be 5 percent.28 No Tc(b+) Caucasians have been 
found. The Tc(a–) phenotype also has been described in 
Caucasians.29 An antibody was detected in the serum of an 
18-year-old woman (DWL) who had been transfused with 
four units of RBCs during her second pregnancy. Her RBCs 
typed as Tc(a–b–), and the antibody was compatible with 
Tc(a–b+) RBCs. A family study showed that the proposi-
ta’s parents and three of four siblings were incompatible, 
but the RBCs of DWL’s serologically compatible sister also 
typed Tc(a–b–) and were nonreactive with the antibody. 
The low-prevalence antigen was named Tcc and is the anti-
thetical antigen of Tca. Six months later, DWL’s serum was 
reactive with Tc(a+b–) and Tc(a–b+) RBCs but not with her 
own RBCs or those from her Tc(a–b–c+) sister. Subsequent 
testing showed that the antibody was compatible with RBCs 
of the Inab phenotype. It was proposed that the antibody 
was an inseparable anti-TcaTcb.29 The molecular basis of the 
Tca/Tcb antigens was defined by direct sequence analysis as 
a single nucleotide change, 155G>T, that is predicted to en-
code Arg52Leu in the CCP1 of DAF.22 Another nucleotide 
change at the same position (155G>C) was found in a Tc(a–
b–c+) sample, which is predicted to encode a change of Ar-
g52Pro.20
Dra
 Another antibody to an apparent Cromer-related high-
prevalence antigen was reported in 1984.15 Before surgery, 
an antibody to a high-prevalence antigen was identified in 
the serum of MD, an Israeli woman of Bukharan origin. In 
family studies, MD’s serum was compatible with the RBCs 
from her sister, whose serum also contained an antibody 
that demonstrated identical specificity. Both women were 
multiparous and had been transfused. The RBCs of both 
MD and her sister had weakened expression of Cra and 
Tca antigens and were only weakly incompatible with the 
Inab serum and that of Owens (see IFC).15 The antibody 
was shown to be distinct from anti-Cra and anti-Tca and 
was named anti-Dra, after MD. Two other examples of anti-
Dra in unrelated individuals of Uzbekistani Jewish descent 
were described.30,31 Family studies performed on the second 
reported example revealed three Dr(a–) individuals, two 
sons and a daughter, none of whom had anti-Dra in their 
serum. Weakened expression of Cra and Tca antigens (and 
subsequently of other high-prevalence Cromer antigens) 
was also observed in these individuals. A 38-year-old Rus-
sian woman (KZ), who presented with a chronic intestinal 
disorder, was originally reported as an example of the Inab 
phenotype, but subsequent studies showed that her Dr(a–) 
RBCs were weakly reactive with anti-Tca and anti-IFC.32,33 
Although KZ’s siblings were not available for testing, sam-
ples from her parents were tested. RBCs from both parents 
were positive for IFC; however, the reactivity was weaker 
than that of control RBCs, consistent with an underlying 
heterozygous genotype which included the silencing/vari-
ant allele. The Dr(a–) phenotype has been also described in 
the Japanese population. Daniels et al.34 reported anti-Dra 
in the serum of a female blood donor who had two children 
but no history of transfusion. The donor’s RBCs reacted 
weakly with anti-Cra, anti-Tca, anti-WESb, anti-UMC, and 
six of nine monoclonal anti-DAFs but did not react with 
anti-Dra. Another Japanese Dr(a–) proband, a blood donor, 
was reported by Uchikawa et al.35 The donor’s RBCs were 
only weakly agglutinated by five monoclonal anti-DAFs and 
with the original anti-IFC, but not by anti-Dra. The molecu-
lar basis is the same for Israelis and Japanese. A single nu-
cleotide change of 596C>T produces Ser199Leu.33,34,36 The 
nucleotide change creates an alternative splice site that is 
used preferentially but not exclusively. However, the mis-
splicing results in a 44–base pair (bp) deletion in the coding 
sequence that alters the open reading frame and results in 
a premature stop codon. The small amount of full-length 
DAF that is translated carries the 199Leu residue, and RBCs 
type as Dr(a–). The Cromer antigens on Dr(a–) RBCs are 
very weak and may not be detected by hemagglutination. 
In tests with monoclonal antibodies, Dr(a–) RBCs express 
only 40 percent DAF when compared with normal RBCs.36 
The Dra antigen is the receptor for fimbriae from 075X-pos-
itive Escherichia coli, an organism that is associated with 
urinary tract infection, cystitis, and protracted diarrhea.37
Esa
 The original antibody found in the serum of a woman 
of Mexican descent was detected in routine compatibility 
testing and was reactive with all random RBCs tested.16 
The RBCs of two of three siblings, as well as RBCs of the 
Inab phenotype, were compatible with the antibody. The 
woman’s parents were first cousins. The second example 
was identified in an African American man who was being 
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treated for Alzheimer’s disease, diabetes, and anemia. He 
had no history of transfusion and no siblings were avail-
able.38 The molecular basis of the Es(a–) phenotype was 
determined to be a single nucleotide change of 239T>A, 
which predicts a change of Ile80Asn in CCP1 of DAF.20
IFC (The Inab or Crnull Phenotype)
 The Inab phenotype is the null phenotype of the Cromer 
blood group system, and the RBCs of people with this rare 
phenotype are DAF-deficient.3 The sera of several of these 
individuals with the Inab phenotype contained an antibody 
that was reactive with all random RBCs tested, including 
RBCs lacking the high-prevalence Cromer antigens. The 
antibody was named anti-IFC, and RBCs of the Inab phe-
notype are IFC negative.17
 To date, this rare phenotype has been identified in nine 
people: five Japanese,3,34,39–41 one Jewish American,42 an 
Italian American woman and her brother,43 and an African 
American34 (Table 2). It is likely that another African Amer-
ican male was also of the Inab phenotype; however, his 
RBCs were never tested.44 The first two probands with the 
Inab phenotype, a Japanese man and a Jewish American 
man, were both diagnosed with disorders of their GI tracts, 
and it was unclear whether the “null” status was an acquired 
phenomenon associated with their disease or an inherited 
characteristic.3,42 However, the parents of the propositus 
were first cousins, suggesting that the Inab phenotype arose 
from the inheritance of a rare recessive gene. The Japanese 
patient, Osad-II,34 was diagnosed with a capillary angioma 
of the small intestine.34 Similarly, the aforementioned African 
American boy had a diagnosis of protein-losing enteropathy,44 
as did the African American patient.34 However, no history 
of intestinal disease was reported in the 86-year-old Italian 
American,43 who had been admitted to the hospital with a 
fractured hip, or for one of the remaining two Japanese in-
dividuals.41
 DAF is important in protecting cells from complement 
attack; thus it was surprising to find that IFC-negative and 
Dr(a–) RBCs that either lack DAF completely or have re-
duced DAF do not show a marked susceptibility to lysis in 
vitro.45,46 The relative stability of the RBCs in these people 
contrasts sharply with the state of RBCs in persons experi-
encing paroxysmal nocturnal hemoglobinuria (PNH). PNH 
III RBCs have a gross deficiency of all GPI-linked glycopro-
teins, of which DAF is just one.47 As DAF is expressed on GI 
tissue,48 it is enticing to speculate that a link exists between 
these patients with the Inab phenotype and their assorted 
GI disorders, although the association of DAF deficiency 
and chronic disease of the intestine remains unproved.
 The molecular basis of the Inab phenotype has been 
determined in the five Japanese probands (Table 2). In 
two people, a nucleotide change of 261G>A is predicted to 
change Trp87 to a stop codon.33,34 In two other Japanese 
Inab people, a nucleotide change of 263C>A introduces a 
cryptic splice site in exon 2.39,40 Use of this splice site re-
sults in a 26-bp deletion and alters the open reading frame. 
As a consequence, Ser88 is changed to a stop codon. In all 
cases, there is no DAF protein in the membrane. A third 
single-nucleotide polymorphism (SNP) found in another 
Japanese individual with the Inab phenotype, 508C>T, is 
predicted to introduce a stop codon in the third CCP do-
main (Arg170Stop) and is likely another silencing change, 
but in the lone report of this single nucleotide change, the 
level of DAF on the propositus’s RBCs was not assayed.41
 There have been several reports of individuals with a 
transient Inab phenotype (Table 2). The first instance was 
in a 54-year-old man from Kenya with a history of HbS trait 
and α-thalassemia.49 He was admitted to the hospital with 
abdominal pain from an enlarged spleen with infarcts that 
eventually required its removal. On admission, the patient 
had an IgG antibody against a high-prevalence antigen that 
behaved like an antibody in the Cromer system, namely 
anti-IFC. His RBCs lacked CD55 and, thus, all the Cromer 
antigens for which he was tested (Cra, Tca, Dra, WESb, UMC, 
IFC), although expression of CD59 was normal, indicating 
that he did not have PNH. Interestingly, this patient had 
been a frequent blood donor up until the time of his illness, 
and no unexpected antibodies had ever been detected in his 
serum. He also did not give a history of any other GI prob-
lems, other than his acute splenomegaly, nor had he been 
transfused. He had a consensus DAF gene. By 17 months af-
ter splenomegaly, the anti-IFC was extremely weak and the 
high-prevalence Cromer antigens had begun to reappear on 
his RBCs, along with CD55. The authors point out that a 
causal link between the patient’s disease and the transient 
Inab phenotype is speculative.

























38 Japanese Yes None No 508C>T
47 Swedish Yes None Yes Unknown
37 Japanese Yes Unknown No 263C>A
46 Kenyan Yes None Yes None





Yes PLE No Unknown
36 Japanese Unknown None No 263C>A
40 Italian- 
American
Yes None No Unknown
Italian- 
American
No None No Unknown
39 American Yes Crohn’s 
disease
No Unknown
3 Japanese Yes PLE No 261G>A
*Reprinted with permission from John Wiley and Sons.4
GERD = gastroesophageal reflux disease; GI = gastrointestinal; 
PLE = protein-losing enteropathy.
J.R. Storry et al.
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 The second example of a patient with a transient Inab 
phenotype was a 78-year-old woman with a history of three 
pregnancies and chronic lymphoblastic leukemia (CLL) that 
appeared to be transforming into the acute variety.50 She 
too initially had anti-IFC in her serum, and her RBCs did 
not express Cra, Dra, Tca, or IFC. During the next 3 months, 
her antibody disappeared and her RBCs began to express 
Cromer RBCs. It is enticing to speculate that the disappear-
ance of this patient’s anti-IFC was related to chemotherapy 
that she might have received for her acute leukemia, but the 
authors did not detail the extent and nature of her treat-
ment, nor did they mention whether she had any GI abnor-
malities. Also, DAF gene sequencing was not reported.
 The third patient with a transient Inab phenotype was 
a very young boy with multiple medical problems includ-
ing congenital cytomegalovirus (CMV), which led to blind-
ness and deafness.4 He was also at the 0 percentile for 
both height and weight, and had severe GI reflux disease 
and some food intolerances. When he was 1 year old, an 
ABO discrepancy was noted and he had an antibody to a 
high-prevalence antigen that reacted at the immediate spin 
phase as well as at IAT. This antibody also behaved like an 
antibody in the Cromer system in terms of its reactivity with 
chemically treated RBCs and its failure to agglutinate Dr(a–), 
IFC–, and PNH III RBCs. Furthermore his RBCs did not 
express Dra, IFC, or CD55; Yta and Emm were present on his 
RBCs, thus excluding PNH. Although this antibody did not 
weakly agglutinate the Dr(a–) RBCs, it was considered to 
be anti-IFC. Exons 2 through 6 of DAF were consensus. He 
had not been transfused before these serologic investiga-
tions. Approximately 6 months later the anti-IFC was virtu-
ally undetectable, and Dra, IFC, and CD55 were beginning 
to be expressed on his RBCs.
WESa, WESb
 In 1987, a low-prevalence antigen, WES, was described 
in the Finnish population, with an occurrence of 0.6 per-
cent.51 The antibody was first detected during routine com-
patibility testing using serum from a 77-year-old woman. 
Subsequently, many more examples of the antibody were 
identified when WES+ RBCs were used to screen donor 
plasma samples. Family studies showed WES to be inher-
ited as an autosomal dominant characteristic. Two further 
examples of WES+ RBCs were found in 392 samples from 
Black American blood donors, and five WES+ donors were 
found in a population of 245 Black North London donors. 
In a study of 3072 American donors drawn in eight differ-
ent blood centers across the United States, 7 of 1460 Black 
donors and 2 of 1612 White donors were WES+, giving an 
occurrence of 0.48 percent and 0.12 percent, respectively.52
 Daniels et al.53 described an antibody to a high-
prevalence antigen produced by a Black WES+ prenatal 
patient (Wash). At delivery, the infant’s RBCs had a weakly 
positive DAT result and the antibody could be eluted, but 
there was no evidence of clinical HDFN. The antibody failed 
to react with a presumed WES+ homozygote of Finnish 
origin (Hel). Both the proposita’s RBCs and those of Hel 
were positive for Cra, Tca, Dra, and other Cromer-related 
antigens. The Wash serum reacted with RBCs lacking high-
prevalence Cromer-related antigens but showed weak re-
activity only with Dr(a–) RBCs and was nonreactive with 
RBCs of the Inab phenotype. Additionally, the serum failed 
to react with α-chymotrypsin–treated or pronase-treated 
RBCs. It was proposed that the antigen recognized by the 
Wash serum was antithetical to WES. The low-prevalence 
antigen WES was renamed WESa and the high-prevalence 
antigen was named WESb. Molecular characterization of 
WESa and WESb showed that the antigens are encoded 
by a single nucleotide difference in codon 48. A change 
of 245T>G of the wild-type DAF results in the loss of the 
WESb antigen and expression of WESa. At the protein level, 
this is predicted to encode a change of Leu82Arg on CCP1 of 
DAF. Tests with anti-WESb showed that Es(a–) RBCs react 
less strongly than Es(a+) RBCs; additionally, WES(a+b–) 
RBCs react very weakly with anti-Esa, reactivity only being 
demonstrable by adsorption or elution tests.31 Because the 
amino acid responsible for the Esa antigen is Ile46, just two 
residues away, this finding is not surprising.20
UMC
 UMC, another high-prevalence antigen of the Cromer 
blood group system, was reported in 1989.54 The only ex-
ample of anti-UMC described was found in the serum of a 
Japanese blood donor. Although untransfused, the propos-
ita had three children. The antibody reacted with all panel 
RBCs tested, including RBCs lacking known high-
prevalence Cromer antigens, although the RBCs of one sib-
ling were compatible, as were the RBCs of a patient with 
PNH and those of the Inab phenotype. Testing of 45,610 
Japanese blood donors did not reveal another UMC– in-
dividual. The molecular basis of the UMC– phenotype was 
shown to be another single nucleotide change of 749C>T, 
which is predicted to encode Thr250Met on CCP4 of DAF.20
GUTI
 An antibody (anti-GUTI) in the serum of a Canadian 
blood donor of Chilean descent was strongly reactive with a 
panel of RBCs of common phenotype.55 Tests after different 
protease treatments showed the antibody reactivity was ab-
lated after treatment of test RBCs with α-chymotrypsin or 
pronase. Treatment with papain, trypsin, or 200 mM DTT 
did not affect reactivity. Subsequent tests with RBCs known 
to lack high-prevalence antigens in the Cromer system and 
with PNH III RBCs showed that the plasma contained an 
antibody to a novel antigen in the Cromer blood group sys-
tem. Molecular analysis of the donor’s blood identified a 
nucleotide change, 719G>A, in DAF that corresponded to 
an amino acid change of Arg240His in CCP4 of DAF.55 Im-
munoblotting analysis using anti-GUTI with DAF deletion 
mutants confirmed the location of the antigen on CCP4. 
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The donor’s parents and two daughters were shown by 
PCR-RFLP analysis to be heterozygous for the nucleotide 
change. One sister was homozygous for normal DAF. An-
other sister was homozygous for the 719A change and her 
RBCs were compatible with anti-GUTI. Screening of more 
than 1000 North American blood donors did not reveal 
any additional GUTI-negative RBCs. PCR-RFLP analy-
sis of DNA samples from 114 Native Chileans showed that 
the polymorphism was present with an occurrence of 5.3 
percent.55
SERF
 The first example of anti-SERF was detected in a preg-
nant Thai patient.56 Her IgG antibody was suspected to be 
against a high-prevalence antigen in the Cromer system 
because it demonstrated the typical reactivity pattern with 
chemically treated RBCs, did not react with IFC– or Dr(a–) 
RBCs, and only reacted weakly against RBCs in which the 
Cromer antigens were transiently suppressed. The antibody 
was confirmed to target DAF using monoclonal antibodies 
in the MAIEA. A single nucleotide change in exon 5 of DAF, 
647C>T, causes a Pro216Leu amino acid substitution in 
the third CCP. These authors56 found the frequency of the 
SERF-negative allele to be 1 percent in a sample of 100 Thai 
individuals, and this frequency was subsequently confirmed 
in a large screening study of 1041 Thai blood donors.57
ZENA
 The first and only example of anti-ZENA was discov-
ered in a pregnant Syrian-Turkish woman whose IgG an-
tibody to a high-prevalence antigen did not react with 
IFC– and Dr(a–) RBCs.19 The reaction of this antibody with 
chemically treated RBCs was consistent with an antibody 
to a Cromer system antigen, although the patient’s Cromer 
phenotype was unremarkable. A novel nucleotide change in 
exon 6 of the DAF gene, 726T>G (His242Gln, in the fourth 
CCP of the DAF protein), was discovered when the gene was 
analyzed. The propositus’s serum reacted with the RBCs 
from a variety of family members, all of whom were shown 
to be heterozygous for this SNP. Consistent with other preg-
nancies complicated by anti-Cromer antibodies, her baby 
was born without evidence of HDFN, and the baby’s DAT 
was negative. No ZENA– individuals were found among the 
150 Israeli blood donors that were screened.19
CROV
 The antibody to this creatively named antigen (from 
CROmer and CROatia + Vinkovci, the city from which the 
proposita hailed) was found in the serum of a woman with 
multiple medical and surgical problems.19 She had been 
pregnant three times but had not been transfused. The anti-
body was an IgG antibody to a high-prevalence antigen that 
failed to react with IFC– RBCs and produced only weak ag-
glutination with Dr(a–) RBCs. The reactivity pattern of anti-
CROV with protease-modified RBCs was also suggestive of an 
antibody in the Cromer system, and her Cromer RBC phe-
notype was unremarkable. The genetic investigation of this 
proposita revealed a nucleotide change in exon 3, 466G>A 
(Glu156Lys, in the second CCP of the DAF protein), and 
similar to the ZENA proposita, her serum agglutinated 
RBCs from some first-degree relatives who were shown to 
be heterozygous for this nucleotide change. As with the 
population screening for ZENA, no further CROV-negative 
alleles were found when 100 Croatian DNA samples were 
tested.19
CRAM
 The first example of anti-CRAM was identified in a So-
mali woman who was in her eighth week of gestation of her 
third pregnancy.19 She had not been transfused. Her IgG an-
tibody to a high-prevalence antigen demonstrated the typi-
cal Cromer pattern of reactivity to chemically treated RBCs, 
did not react with IFC– RBCs, and reacted only weakly 
with Dr(a–) RBCs and those with a transient suppression 
of Cromer system antigens. Her Cromer phenotype was 
pedestrian. Monoclonal antibodies specific to the first CCP 
of the DAF protein caused RBC agglutination, although an-
other monoclonal antibody to CCP 3 or 4 did not cause ag-
glutination, thereby revealing the location of the amino acid 
change, Gln247Arg in the fourth CCP, caused by a 740A>G 
nucleotide change in exon 6 of DAF. The authors indicted 
that it was not possible for them to perform screening of 
Somali individuals—thus, the frequency of this allele in 
this population is not known—and cautioned that although 
some Cromer alleles are prevalent in certain populations, it 
is premature to link an allele to the ethnicity of a proband.19
Characteristics of Cromer Antigens
 Cromer blood group antigens are sensitive to treatment 
of RBCs with α-chymotrypsin or pronase, but they are not 
affected by treatment with trypsin, papain, or ficin.31,58 
Reducing agents such as 2-aminoethylisothiouronium bro-
mide (AET), 2-ME, or DTT weaken the antigens but 
generally do not disrupt them completely.31 This is some-
what surprising, as DAF is known to have a number of in-
trachain disulfide bonds and the protein is detectable by 
immunoblotting techniques only under nonreducing con-
ditions.4 Although DAF is a cell membrane–bound glyco-
protein, small amounts are present in the plasma and other 
body fluids of normal individuals.5,48 Hemagglutination in-
hibition studies have shown that antibodies to Cromer an-
tigens may be inhibited by concentrated plasma and urine 
from an antigen-positive person.31 In one study by Judd et 
al.,59 a commercial preparation of human platelet concen-
trates for immunohematologic use was shown to adsorb 
anti-Cra from four different sera. The authors warned of the 
potential hazards of using such preparations, designed for 
the removal of HLA antibodies, in the adsorption of poten-
tially clinically significant antibodies.
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Clinical Significance of Cromer Antibodies
 Because persons lacking the various high-prevalence 
antigens of the Cromer blood group system are rare, there 
are few suitable donors for patients who are sensitized. 
In vivo and in vitro survival studies have been used to 
determine the consequences of transfusing antigen- 
positive RBCs to sensitized patients. In vitro studies, such 
as the mononuclear phagocyte assay (MPA) or the mono-
cyte monolayer assay (MMA), suggested that these anti-
bodies could be clinically significant.14,59–63 A number of in 
vivo chromium 51 (51Cr) -labeled RBC survival studies with 
Cr(a+) RBCs have been reported.23,44,59,62,64–66 With the ex-
ception of one case,66 increased destruction of incompatible 
RBCs, albeit variable, was observed. However, Smith et al.23 
reported the uneventful transfusion of a patient with anti-
Cra with two units of Cr(a+) RBCs. Based on the results of 
a 51Cr survival study in one patient, Ross and McCall64 pro-
posed that incompatible blood could be transfused “with-
out significant untoward effect.” In a case described by 
Whitsett and Oxendine,66 normal survival of Cr(a+) RBCs 
was observed in a patient with anti-Cra. The antibody was 
reactive in an MMA and was IgG. Two incompatible units 
were transfused successfully, as determined by the absence 
of clinical signs of hemolysis. Kowalski et al.67 reported a 
hemolytic transfusion reaction in a woman who was trans-
fused with three units of crossmatch-compatible RBCs. 
Seven days after transfusion, the patient’s hemoglobin had 
dropped to 5.5 g/dL with no overt signs of bleeding. Anti-Tca 
was identified in the posttransfusion serum, and an MMA 
was strongly reactive. Anderson et al.65 observed decreased 
RBC survival of incompatible RBCs in a patient with anti-
Tca, and there was no increase in antibody titer. RBC sur-
vival at 16 days was normal.
 Although the antigens of the Cromer blood group sys-
tem are well developed on fetal RBCs near term, there have 
been no cases of fetal demise directly attributed to these 
antibodies. This might appear somewhat anomalous, as 
Cromer antibodies are mostly IgG, predominantly of the 
IgG1 subclass, and would be expected to cross the pla-
centa.51,62,68 Elegant studies on human trophoblast cells by 
Holmes et al.69 showed that there was an elevated concen-
tration of DAF on cells at the immediate fetomaternal inter-
face, and proposed that the elevated concentration of DAF 
in the trophoblast is a protection mechanism of the fetus 
against complement-mediated maternal attack. Support for 
this hypothesis was demonstrated in a case of a postpartum 
woman whose anti-Cra was elutable from the placenta itself 
even though the antibody was not present in her plasma or 
that of her newborn.70
 That the placenta can become a “sink” for Cromer anti-
bodies is supported by six different case reports: four wom-
en whose serum contained anti-Cra with titers that were 
at least 64 in the first trimester and the patient with anti-
CRAM whose antibody titered to 128 in her second trimes-
ter19 demonstrated loss of reactivity of the antibody as the 
pregnancy progressed, in at least two cases to undetectable 
levels at delivery. (Anti-CRAM was not detectable 1 month 
before parturition; thus, it was probably not detectable at 
the time the baby was born.19) Another woman, whose se-
rum contained anti-Dra with a titer of 512 at 22 weeks, had 
no detectable antibody at delivery. The DAT performed on 
the cord RBCs of five of these babies was negative (in the lone 
anti-CRAM case the neonatal DAT was not reported19), and 
there was no evidence of HDFN in any of these cases.25,71,72 
In three of the cases the antibody, including anti-CRAM, 
was detected again in the serum of these women after deliv-
ery, again suggesting an adsorption mechanism rather than 
the cessation of antibody production.19,71 Although no cases 
of fetal demise have been directly attributed to Cromer an-
tibodies, it is worthwhile to point out that in at least one 
case, anti-Cra was detectable at a titer of 128 by week 15 and 
had declined to a titer of 8 by week 20, which was 2 weeks 
before fetal demise. The role of the antibody in the demise 
is not known, and this patient’s next pregnancy was suc-
cessfully carried to term despite the presence of anti-Cra at 
a maximum titer of 64 at week 7.70 Interestingly, a patient 
with an anti-Dra titer that ranged between 256 and 512 gave 
birth to two babies who were not affected by HDFN despite 
one baby’s having a positive DAT with anti-Dra recoverable 
in the eluate.73 The titer of the anti-Dra in this woman did 
not change appreciably during either pregnancy.
Conclusions
 The Cromer blood group system consists of 2 pairs of 
antithetical antigens (Tca/Tcb/Tcc and WESa/WESb) and 
10 high-prevalence antigens on DAF that are characterized 
serologically by their sensitivity to α-chymotrypsin and 
pronase. With the exception of IFC, molecular analysis has 
shown that each antigen is the result of a single nucleotide 
change in DAF that affects a single amino acid in the result-
ing protein. In general, the different phenotypes demon-
strate an ethnic bias that suggests a spontaneous mutation 
in that population. The recent identification of four new 
Cromer system antigens suggests that there are probably 
other rare and exciting polymorphisms of DAF that await 
discovery.
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